Author

Silke Appel‐Dingemanse

Observed names: S APPELDINGEMANSE, S Appel-Dingemanse, S DINGEMANSE, S. Appel Dingemanse, S. Appel-Dingemanse, S. Appel‐Dingemanse, Silke Appel-Dingemanse, Silke Appeldingemanse

Institution: Novartis (Switzerland)

Observed institutions: Novartis (Switzerland), University of California, Los Angeles

OpenAlex ID: A5089523988

Tegaserod, a 5‐HT 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

2001 · L. Degen, D. Matzinger, et al. · Alimentary Pharmacology & Therapeutics · 211

PDF

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients

2007 · G Lefèvre, G Sędek, et al. · Clinical Pharmacology & Therapeutics · 130

A Phase I Study of a 4-week Course of Sdz-rad (rad) in Quiescent Cyclosporine-prednisone-treated Renal Transplant Recipients1,2

1999 · Barry D. Kahan, Robert L. Wong, et al. · Transplantation · 109

Rivastigmine exposure provided by a transdermal patch versus capsules

2007 · François Mercier, Gilbert Lefèvre, et al. · Current Medical Research and Opinion · 78

Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development

2007 · Jasper Dingemanse, Silke Appel-Dingemanse · Clinical Pharmacokinetics · 75

Pharmacokinetic rationale for the rivastigmine patch

2007 · Jeffrey Cummings, Gilbert Lefèvre, et al. · Neurology · 73

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

2002 · Joel Morganroth, Peter C. Ruegg, et al. · The American Journal of Gastroenterology · 70

Clinical Pharmacokinetics of Tegaserod, a Serotonin 5-HT4 Receptor Partial Agonist with Promotile Activity

2002 · Silke Appel-Dingemanse · Clinical Pharmacokinetics · 59

Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism

2009 · Natalie L. Trevaskis, David M. Shackleford, et al. · Pharmaceutical Research · 53

Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

2008 · Gilbert Lefèvre, Françoise Pommier, et al. · The Journal of Clinical Pharmacology · 45

Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT4 receptor agonist, following oral and intravenous administration

1999 · Silke Appel‐Dingemanse, Marie‐Odile Lemarechal, et al. · British Journal of Clinical Pharmacology · 40

PDF

Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety

2009 · Anne Gardin, Klaus Kucher, et al. · Drug Metabolism and Disposition · 32

RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis

2001 · Ramona L Doyle, Marshall I Hertz, et al. · The Journal of Heart and Lung Transplantation · 30

2009 · Gilbert Lefèvre, Monika Büche, et al. · The Journal of Clinical Pharmacology · 25

2007 · D. Tuerck, Y. Wang, et al. · International Journal of Clinical Pharmacology and Therapeutics · 23

The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young

2001 · S. Appel‐Dingemanse, A. Horowitz, et al. · Alimentary Pharmacology & Therapeutics · 22

Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919)

2001 · S. Appel-Dingemanse, Y. Hirschberg, et al. · European Journal of Clinical Pharmacology · 20

The Effects of Tegaserod (HTF 919) on the Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects

2001 · Honghui Zhou, Patricia C. Ledford, et al. · The Journal of Clinical Pharmacology · 18

Pharmacokinetics of Fluvastatin in Subjects with Renal Impairment and Nephrotic Syndrome

2002 · S. Appel‐Dingemanse, T. Smith, et al. · The Journal of Clinical Pharmacology · 15

Tegaserod Coadministration Does Not Alter the Pharmacokinetics of Theophylline in Healthy Subjects

2001 · Honghui Zhou, Suzanne Khalilieh, et al. · The Journal of Clinical Pharmacology · 15

Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects

2003 · Suzanne K. Swan, Honghui Zhou, et al. · The Journal of Clinical Pharmacology · 12

Tegaseroid (HTF 919), a partial 5-HT4 receptor agonist, accelerates gastrointestinal (GI) transit

2000 · Lukas Degen, Daniel Matzinger, et al. · Gastroenterology · 12

Dose‐Proportional Pharmacokinetics of d‐threo‐Methylphenidate After a Repeated‐Action Release Dosage Form

2006 · Dietrich Tuerck, Silke Appel‐Dingemanse, et al. · The Journal of Clinical Pharmacology · 11

Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects

2000 · Honghui Zhou, Yulia H. Walter, et al. · Gastroenterology · 11

PDF

Effect of gastric ph on plasma concentrations of tegaserod (HTF 919) and its major metabolite in healthy subjects

2000 · Honghui Zhou, Sauzanne Khalilieh, et al. · Gastroenterology · 6

Works count: 38

Citation count: 1,219

H-index: 18

I10-index: 24